Search Results
May 21, 2025, 10:15 ET Liquid Handling System Market worth US$7.4 billion by 2030 with 8.0% CAGR | MarketsandMarkets™
applications), clinical diagnostics (sample preparation, ELISA, other clinical diagnostics applications), genomics (genotyping, next-generation sequencing (NGS), polymerase chain reaction (PCR), DNA/RNA purification, gene expression analysis, other genomics applications), proteomics, cell and gene therapy, forensic
More news about: MarketsandMarkets
May 20, 2025, 19:11 ET n6 baut europäische Präsenz aus, um Wissenschaftler zu unterstützen und NGS-Workflows zu vereinfachen
und aus erster Hand zu erfahren, wie n6 die Zukunft der NGS-Workflows gestaltet. Informationen zu n6n6 hat es sich zur Aufgabe gemacht, Wissenschaftlern innovative, benutzerfreundliche Lösungen zur Verfügung zu stellen, die NGS-Workflows rationalisieren und die Forschung beschleunigen.
More news about: n6
May 20, 2025, 09:14 ET n6 Expands European Presence to Empower Scientists and Simplify NGS Workflows
attendees to visit Stand 1202 to experience firsthand how n6 is shaping the future of NGS workflows. About n6n6 is dedicated to empowering scientists with innovative, easy-to-use solutions that streamline NGS workflows and accelerate discovery. With a customer-first mindset and a passion for
More news about: n6
May 19, 2025, 22:56 ET SPOT-MAS Lung： AI 賦能的血液檢測為亞洲高風險非吸煙人群帶來新曙光
4,500 多家醫院和診所合作，擁有一支由約 250 名生物學專家和技術人員組成的專業團隊，員工總數達 700 人。 Gene Solutions 已發表 50 多篇同行評審的論文，並開展了 50 多項多中心研究，其自主研發成果以及位於新加坡和越南的 CAP 認證的新一代測序 (NGS) 實驗室備受認可。該公司將多維基因組學與AI驅動分析方法相結合，推動癌症診療模式的革新。 參考文獻 (1) GLOBOCAN 2020 – Global Cancer Observatory, Lung Cancer Statistics (2)
More news about: Gene Solutions Genomics Pte Ltd
May 16, 2025, 09:00 ET BillionToOne Launches Expanded Panel for UNITY Fetal Risk™ Screen, Setting New Standard in Prenatal Testing
precision diagnostics company on a mission to make molecular diagnostics more powerful, accurate, and accessible for all. The company's single-molecule NGS (smNGS) platform, which includes the patented Quantitative Counting Template (QCT) technology, is the only multiplex methodology that can accurately
More news about: BillionToOne
May 16, 2025, 07:57 ET Pangea Laboratory Appoints John Moore as Chief Executive Officer
Pangea Laboratory, a leader in the development of advanced cancer diagnostics and microbiome Next-Generation Sequencing (NGS) testing, is proud to announce the appointment of John Moore as its new Chief Executive Officer. Mr. Moore brings
More news about: Pangea Laboratory
May 15, 2025, 16:30 ET ePlus Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date and Conference Call
HERNDON, Va., May 15, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
May 15, 2025, 15:19 ET Single-Cell Genomics and Proteomics: Leading the Future of Biomedical Research
protein profiles.The idea of studying cells individually dates back to the 19th century.Next-generation sequencing (NGS) and mass spectrometry have recently made large-scale single-cell analysis possible.These techniques have revealed unexpected diversity
More news about: BCC Research LLC
May 15, 2025, 10:01 ET In Vitro Diagnostics Market Share worth $150.13 billion, Globally by 2030 - Exclusive Report by The Research Insights
stronger demand for diagnostic testing methods that are both precise and prompt. Advancements in molecular diagnostics and next-generation sequencing (NGS) and liquid biopsy methods are improving test precision and speed which helps healthcare providers focus more on precise treatments. Quick and mobile
More news about: The Research Insights
May 15, 2025, 02:24 ET Tsingke Showcases at AACR 2025 -- Advancing Global Cancer Research with Integrated Synthesis Solutions
Acid SynthesisCustom DNA/RNA oligos, siRNA, ASOComplex modifications: LNA, phosphorothioate, dual-labeled probesqPCR and NGS-grade primer/probe productionmRNA Synthesis & Raw Materials SupplyIVT template synthesis with 5'/3' modifications and Poly(A) tailsHigh-purity
More news about: Tsingke Biotech
May 15, 2025, 02:12 ET Tsingke Showcases at AACR 2025 -- Advancing Global Cancer Research with Integrated Synthesis Solutions
Acid SynthesisCustom DNA/RNA oligos, siRNA, ASOComplex modifications: LNA, phosphorothioate, dual-labeled probesqPCR and NGS-grade primer/probe productionmRNA Synthesis & Raw Materials SupplyIVT template synthesis with 5'/3' modifications and Poly(A) tailsHigh-purity
More news about: Tsingke Biotech
May 14, 2025, 10:01 ET CRISPR Market worth US$5.47 billion by 2030 with 11.2% CAGR | MarketsandMarkets™
NGS-based RNA-sequencing Market Get access to the latest updates on
More news about: MarketsandMarkets
May 13, 2025, 15:05 ET Liquid Biopsy Market Boom: Tools, Services, and Diagnostics Unveiled
prenatal screening. Based on biomarker type and analysis platforms, the market segments include cell free nucleic acids, circulating tumor cells, and NGS, and PCR. 3. Which application type will be dominant throughout the forecast period? Non-invasive prenatal screening
More news about: BCC Research LLC
May 13, 2025, 09:15 ET Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
continues DRAGEN's best-in-class accuracy with a 30% improvement in germline structural variant calling accuracy. DRAGEN v4.4 enhancements will simplify NGS analysis for customers while expanding their capabilities.
More news about: Illumina, Inc.
May 12, 2025, 10:00 ET ePlus Customer Experience VP Deanna Davenport Spotlighted on the CRN 2025 Women of the Channel Power 80 Solution Provider List
HERNDON, Va., May 12, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
May 12, 2025, 06:30 ET Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients
Comprehensive Molecular Profiling: Caris utilizes a multi-platform approach, including immunohistochemistry (IHC) and next-generation sequencing (NGS), to provide a detailed molecular profile of NSQ NSCLC tumors. Identification of Actionable Targets: The MET IHC testing helps identify
More news about: Caris Life Sciences
May 09, 2025, 10:01 ET In Vitro Diagnostics Market worth US$157,632.5 million by 2030 with 7.6% CAGR | MarketsandMarkets™
enhanced demand for precise and timely diagnostic testing. Emerging technologies in fields such as molecular diagnostics, next-generation sequencing (NGS), and liquid biopsy are enhancing the accuracy and pace of these tests, which is contributing to the shift of healthcare toward more targeted treatments.
More news about: MarketsandMarkets
May 07, 2025, 10:15 ET Companion Diagnostics Market Set to Surpass USD 12 Billion by 2031 with a CAGR of 13.2% - Discover Key Insights Now! Valuates Reports
patient's response to targeted therapies. NGS-based companion diagnostics are particularly vital in oncology, where treatment effectiveness varies greatly among individuals. Pharmaceutical companies increasingly collaborate with diagnostic developers to pair NGS-based tests with specific drugs, ensuring
More news about: Valuates Reports
May 07, 2025, 10:10 ET Geneseeq Unveils Groundbreaking Blood Test for Early Detection of Pancreatic Cancer
Geneseeq: Geneseeq Technology Inc. (Geneseeq) is a research-driven leader in precision oncology, utilizing cutting-edge next-generation sequencing (NGS) technologies to advance cancer care. The company provides comprehensive genomic profiling solutions for all tumor types, including pan-cancer and cancer-specific
More news about: Geneseeq Technology Inc.
May 07, 2025, 10:05 ET In Vitro Diagnostics Market Size to be Worth $150.13 Billion by 2030 at CAGR 5.62% - Grand View Research, Inc.
The IVD market demonstrates a high degree of innovation, driven by advancements in molecular diagnostics, next-generation sequencing (NGS), and point-of-care testing.The distribution channels for in vitro diagnostics (IVD) market play a critical role in how products reach healthcare
More news about: Grand View Research, Inc.
May 07, 2025, 10:00 ET Eurofins Viracor Revolutionizes Respiratory Diagnostics with New BAL Specimen Type for NeXGen® Fungal / AFB NGS Assay
launches BAL specimen testing for NeXGen Fungal/AFB NGS assay.Traditional methods for diagnosing these infections, such as cultures, are often time-consuming and may miss atypical or slow-growing species. The NeXGen® Fungal / AFB NGS assay overcomes these limitations by utilizing the
More news about: Viracor Eurofins
May 06, 2025, 08:09 ET Cellecta, Inc. Launches Blood Microsampling Assay that Profiles 19,000 Human Protein-Coding Genes from One Drop of Dried Blood
protein-coding genes from as little as 30 microliters of dried whole blood. The assay combines multiplex RT-PCR and next-generation sequencing (NGS) enabling researchers to generate comprehensive, easy-to-analyze data from remotely collected droplets of blood captured using Trajan Scientific and
More news about: Cellecta, Inc.
May 05, 2025, 11:50 ET Psomagen Selected as Key Service Provider, Will Utilize Ultima Genomics' UG 100™ Sequencer to Accelerate Chan Zuckerberg Initiative's Billion Cells Project
Ultima Genomics UG 100 high throughput NGS sequencer, for which
More news about: Psomagen Inc
May 01, 2025, 09:15 ET Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
effectiveness and side effects of GLP-1 receptor agonists across individual patients." The initiative leverages end-to-end Illumina NGS technologies to sequence 25,000 whole genomes and to profile the protein expression of 5000 samples, using the Illumina Protein Prep (IPP) assay, which
More news about: Illumina, Inc.
Apr 29, 2025, 08:00 ET NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
solutions that enable precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary ultra-high throughput next-generation sequencing (NGS) platform, today announced a collaboration to use Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance NeoGenomics' ability to
More news about: Ultima Genomics